-continued















-continued









28. The conjugate of claim **27**, wherein the conjugate has a folate receptor relative affinity of about 0.1 or greater compared to folic acid.

29. The conjugate of claim **27**, wherein the conjugate has a folate receptor relative affinity of about 0.2 or greater compared to folic acid.

30. The conjugate of claim **27**, wherein the conjugate has a folate receptor relative affinity of about 0.5 or greater compared to folic acid.

31. The conjugate of claim **27**, wherein m is 1 or 2.

32. The conjugate of claim **27**, wherein m is 1.

33. The conjugate of claim **27**, wherein the linker further comprises at least one releasable linker that is not a disulfide.

34. The conjugate of claim **27**, wherein the linker further comprises at least two releasable linkers.

35. The conjugate of claim **27**, wherein at least one releasable linker that is not a disulfide.

36. The conjugate of claim **27**, wherein at least one D is selected form the group consisting of vinca alkaloids, tubulysins, mitomycins, and epothilones.

37. A pharmaceutical composition comprising the conjugate of claim **27**, and one or more carriers, excipients, diluents, and combinations thereof.

38. A method for treating a pathogenic population of cells in a patient, the method comprising administering an effec-